{"id":"maxacalcitol","rwe":[{"pmid":"41137524","year":"2026","title":"Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long-Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod-Induced Psoriasiform Dermatitis.","finding":"","journal":"The Journal of dermatology","studyType":"Clinical Study"},{"pmid":"40898769","year":"2025","title":"Maxacalcitol alleviates diabetes-associated periodontitis in male mice by restoring Treg/Th17 balance via SOCE-mediated mitochondrial dysfunction.","finding":"","journal":"Journal of periodontology","studyType":"Clinical Study"},{"pmid":"40833047","year":"2025","title":"The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.","finding":"","journal":"Clinical nephrology","studyType":"Clinical Study"},{"pmid":"40497178","year":"2025","title":"Psoriatic Skin Lesions Induced by the Bacillus Calmette-Guerin (BCG) Vaccination in a Child With Latent Tuberculosis Infection: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"40088333","year":"2025","title":"Unlocking the therapeutic potential of the NFAT pathway in kidney diseases.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"maxacalcitol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vitamin D3 receptor","category":"target"},{"label":"VDR","category":"gene"},{"label":"Active","category":"status"},{"label":"Pustular psoriasis","category":"indication"},{"label":"Anticarcinogenic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":907.914,"date":"","count":118,"signal":"Shunt stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 118 times (LLR=908)"},{"llr":488.125,"date":"","count":70,"signal":"Shunt occlusion","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=488)"},{"llr":159.436,"date":"","count":36,"signal":"Peripheral arterial occlusive disease","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=159)"},{"llr":90.952,"date":"","count":26,"signal":"Angina unstable","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=91)"},{"llr":74.064,"date":"","count":42,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=74)"},{"llr":60.652,"date":"","count":9,"signal":"Shunt infection","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=61)"},{"llr":54.667,"date":"","count":23,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=55)"},{"llr":48.635,"date":"","count":6,"signal":"Shunt aneurysm","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=49)"},{"llr":46.363,"date":"","count":21,"signal":"Hypocalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=46)"}],"commonSideEffects":[{"effect":"Shunt stenosis","drugRate":"LLR 908","severity":"serious"},{"effect":"Shunt occlusion","drugRate":"LLR 488","severity":"common"},{"effect":"Peripheral arterial occlusive disease","drugRate":"LLR 159","severity":"common"},{"effect":"Angina unstable","drugRate":"LLR 91","severity":"common"},{"effect":"Cardiac failure","drugRate":"LLR 74","severity":"common"},{"effect":"Shunt infection","drugRate":"LLR 61","severity":"common"},{"effect":"Cerebral infarction","drugRate":"LLR 55","severity":"common"},{"effect":"Shunt aneurysm","drugRate":"LLR 49","severity":"common"},{"effect":"Hypocalcaemia","drugRate":"LLR 46","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oxarol","offLabel":[],"synonyms":["22-oxacalcitriol","maxacalcitol","oxarol"],"timeline":[],"approvals":[],"brandName":"Oxarol","ecosystem":[{"indication":"Pustular psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"certolizumab pegol","slug":"certolizumab-pegol","company":"Ucb Inc"},{"name":"deucravacitinib","slug":"deucravacitinib","company":"Bristol-Myers Squibb"},{"name":"infliximab","slug":"infliximab","company":"Centocor Inc"}],"globalPrevalence":125000000}],"mechanism":{"target":"Vitamin D3 receptor","targets":[{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"}],"modality":"Small Molecule","drugClass":"maxacalcitol","explanation":"Imagine your skin cells are like a row of houses. The Vitamin D3 receptor is like the city planner that decides how many houses to build and where to put them. Maxacalcitol is like a special instruction that tells the city planner to slow down the building process, which helps to reduce the severity of pustular psoriasis.","oneSentence":"Maxacalcitol works by binding to the Vitamin D3 receptor, which helps regulate skin cell growth and differentiation.","technicalDetail":"Maxacalcitol is a synthetic vitamin D3 analog that selectively binds to the Vitamin D3 receptor, activating the retinoid X receptor (RXR) and inhibiting the transcription of genes involved in keratinocyte proliferation and differentiation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1638","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MAXACALCITOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MAXACALCITOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:30:41.444192","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:40:34.793372+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"calcifediol","drugSlug":"calcifediol","fdaApproval":"1980-08-05","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"calcipotriene","drugSlug":"calcipotriene","fdaApproval":"1993-12-29","patentExpiry":"May 7, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-target"},{"drugName":"doxercalciferol","drugSlug":"doxercalciferol","fdaApproval":"1999-06-09","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ergocalciferol","drugSlug":"ergocalciferol","fdaApproval":"1941-01-11","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"paricalcitol","drugSlug":"paricalcitol","fdaApproval":"1998-04-17","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"maxacalcitol","indications":{"approved":[{"name":"Pustular psoriasis","source":"DrugCentral","snomedId":200973000,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"calcifediol","brandName":"calcifediol","genericName":"calcifediol","approvalYear":"1980","relationship":"same-target"},{"drugId":"calcipotriene","brandName":"calcipotriene","genericName":"calcipotriene","approvalYear":"1993","relationship":"same-target"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-target"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-target"},{"drugId":"doxercalciferol","brandName":"doxercalciferol","genericName":"doxercalciferol","approvalYear":"1999","relationship":"same-target"},{"drugId":"ergocalciferol","brandName":"ergocalciferol","genericName":"ergocalciferol","approvalYear":"1941","relationship":"same-target"},{"drugId":"paricalcitol","brandName":"paricalcitol","genericName":"paricalcitol","approvalYear":"1998","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT00828347","phase":"NA","title":"Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2008-01","conditions":["Secondary Hyperparathyroidism"],"enrollment":35,"completionDate":"2009-07"},{"nctId":"NCT01341782","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-05","conditions":["Secondary Hyperparathyroidism","Hemodialysis"],"enrollment":255,"completionDate":"2012-04"},{"nctId":"NCT00667576","phase":"PHASE2","title":"Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-04","conditions":["Chronic Kidney Disease on Hemodialysis","Secondary Hyperparathyroidism"],"enrollment":153,"completionDate":"2009-03"},{"nctId":"NCT00990704","phase":"PHASE2","title":"Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-10","conditions":["Secondary Hyperparathyroidism","Hemodialysis"],"enrollment":47,"completionDate":"2010-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"N2UJM5NBF6","CHEBI":"CHEBI:31801","INN_ID":"7438","UMLSCUI":"C0043872","ChEMBL_ID":"CHEMBL333950","KEGG_DRUG":"D01098","DRUGBANK_ID":"DB06272","PDB_CHEM_ID":" MCZ","PUBCHEM_CID":"6398761","IUPHAR_LIGAND_ID":"2784","MESH_SUPPLEMENTAL_RECORD_UI":"C051883"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":159,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41137524","title":"Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long-Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod-Induced Psoriasiform Dermatitis.","journal":"The Journal of dermatology"},{"date":"2025 Sep 2","pmid":"40898769","title":"Maxacalcitol alleviates diabetes-associated periodontitis in male mice by restoring Treg/Th17 balance via SOCE-mediated mitochondrial dysfunction.","journal":"Journal of periodontology"},{"date":"2025 Nov","pmid":"40833047","title":"The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.","journal":"Clinical nephrology"},{"date":"2025 May","pmid":"40497178","title":"Psoriatic Skin Lesions Induced by the Bacillus Calmette-Guerin (BCG) Vaccination in a Child With Latent Tuberculosis Infection: A Case Report.","journal":"Cureus"},{"date":"2025 Aug","pmid":"40088333","title":"Unlocking the therapeutic potential of the NFAT pathway in kidney diseases.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxarol, also known as Maxacalcitol, is a small molecule used in the treatment of Secondary Hyperparathyroidism, Chronic Kidney Disease on Hemodialysis, and Hemodialysis. It is administered in various doses, including 1.0 μg/day and 0.25 μg/day Alfacalcidol, and has been studied in clinical trials as a maintenance therapy after intravenous treatment.","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:40:34.793372+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}